Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Solid Tumor
Interventions: BIOLOGICAL: IMF-001
Sponsor: ImmunoFrontier, Inc.